Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof
OwnerBrian Stuart Murphyinventor
Life of this patent
Estimating the term…
Abstract
Described are pharmaceutical compositions for treating an inflammatory condition, a neurologic condition and/or a vascular condition, the composition including i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator. Further described are methods of treating inflammatory, neurologic and/or vascular conditions.
Claims20
A method of treating post-infectious encephalopathy comprising administering to a subject i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator.
A method of treating post COVID-19 syndrome comprising administering to a subject i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator;
- wherein the NMDA receptor modulator is an agonist, an antagonist, or a mixed agonist-antagonist at one or more of the NMDA receptor modulator, the 5-HT3 receptor modulator, the nicotinic acetylcholine receptor modulator, the dopamine D2 receptor modulator, or the sigma-1 receptor modulator;
- wherein the modulator compound is an NMDA receptor antagonist;
- wherein the modulator compound is glutamatergic NMDA receptor antagonist;
- wherein the modulator compound is 5-HT3 receptor antagonist;
- wherein the modulator compound is a nicotinic acetylcholine receptor antagonist;
- wherein the modulator compound is a dopamine D2 receptor agonist;
- wherein the modulator compound is a sigma-1 receptor agonist;
- wherein the modulator compound is memantine, a prodrug thereof, an analog thereof, a metabolite thereof or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator.
Dependencies are inferred from the claim text.